Skip to main content
Erschienen in: Sexuality Research and Social Policy 4/2022

08.06.2022

Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17–24 Years Old in the USA

verfasst von: Benedikt Pleuhs, Jennifer L. Walsh, Katherine G. Quinn, Andrew E. Petroll, Alan Nyitray, Steven A. John

Erschienen in: Sexuality Research and Social Policy | Ausgabe 4/2022

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Introduction

HIV and human papillomavirus (HPV) are common sexually transmitted infections among young sexual minority men (YSMM) that are prevented by pre-exposure prophylaxis (PrEP) and HPV vaccination, respectively. We sought to determine the association between a history of PrEP use and HPV vaccination uptake among YSMM.

Methods

Data were collected from an online survey of YSMM (n = 287; Mage = 20.6 years; range: 17–24; 58% Black or Latinx) recruited from social media and men-for-men geosocial networking apps in 2020 and analyses were conducted using chi-squared comparisons and Poisson regression using STATA (IC) version 15.1.

Results

About half (45.0%) of YSMM reported receiving at least one dose of the HPV vaccine. Controlling for other factors, YSMM who were living with HIV or had used PrEP were significantly more likely to have received at least one dose of an HPV vaccine (PR = 2.48, 95% CI = 1.52–4.07; PR = 1.70, 95% CI = 1.26–2.31, respectively).

Conclusions

YSMM living with HIV or with PrEP use experience reported higher rates of HPV vaccination compared to their counterparts, potentially due to greater utilization of health care or contacts with providers attuned to their health needs. Nevertheless, HPV vaccination uptake is suboptimal given the high prevalence of high-risk HPV genotypes among YSMM.

Policy Implications

Standard of care for YSMM should include revisiting HPV vaccination status and discussion of PrEP and other HIV prevention methods given suboptimal rates of HPV vaccination and PrEP uptake among this priority population for HPV, anal cancer, and HIV prevention.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
Zurück zum Zitat Ash, M. A., & Lee Badgett, M. V. (2006). Separate and unequal: The effect of unequal access to employment-based health insurance on same-sex and unmarried different-sex couples. Contemporary Economic Policy, 24(4), 582–599.CrossRef Ash, M. A., & Lee Badgett, M. V. (2006). Separate and unequal: The effect of unequal access to employment-based health insurance on same-sex and unmarried different-sex couples. Contemporary Economic Policy, 24(4), 582–599.CrossRef
Zurück zum Zitat Boersma, P., & Black, L. I. (2020). Human papillomavirus vaccination among adults aged 18–26, 2013–2018. NCHS Data Brief, 354, 1–8. Boersma, P., & Black, L. I. (2020). Human papillomavirus vaccination among adults aged 18–26, 2013–2018. NCHS Data Brief, 354, 1–8.
Zurück zum Zitat Centers for Disease Control and Prevention. (2011). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. Morbidity and Mortality Weekly Report, 60(50), 1705–1708. Centers for Disease Control and Prevention. (2011). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. Morbidity and Mortality Weekly Report, 60(50), 1705–1708.
Zurück zum Zitat Centers for Disease Control and Prevention. (2013). Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR. Morbidity and Mortality Weekly Report, 62(23), 463–465. Centers for Disease Control and Prevention. (2013). Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR. Morbidity and Mortality Weekly Report, 62(23), 463–465.
Zurück zum Zitat Centers for Disease Control and Prevention. (2020a). Cancers associated with human papillomavirus, United States–2013–2017. MMWR. Morbidity and Mortality Weekly Report, 69(37), 1283–1287.CrossRef Centers for Disease Control and Prevention. (2020a). Cancers associated with human papillomavirus, United States–2013–2017. MMWR. Morbidity and Mortality Weekly Report, 69(37), 1283–1287.CrossRef
Zurück zum Zitat Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Bangkok Tenofovir Study, G. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083–2090. https://doi.org/10.1016/S0140-6736(13)61127-7CrossRef Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Bangkok Tenofovir Study, G. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083–2090. https://​doi.​org/​10.​1016/​S0140-6736(13)61127-7CrossRef
Zurück zum Zitat Clift, J. B., & Kirby, J. (2012). Health care access and perceptions of provider care among individuals in same-sex couples: Findings from the Medical Expenditure Panel Survey (MEPS). Journal of Homosexuality, 59(6), 839–850.CrossRefPubMed Clift, J. B., & Kirby, J. (2012). Health care access and perceptions of provider care among individuals in same-sex couples: Findings from the Medical Expenditure Panel Survey (MEPS). Journal of Homosexuality, 59(6), 839–850.CrossRefPubMed
Zurück zum Zitat Dillner, J., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., & Haupt, R. (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ, 341, c3493. https://doi.org/10.1136/bmj.c3493CrossRefPubMed Dillner, J., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., & Haupt, R. (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ, 341, c3493. https://​doi.​org/​10.​1136/​bmj.​c3493CrossRefPubMed
Zurück zum Zitat Markowitz, L. E., Dunne, E. F., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J., & Unger, E. R. (2014). Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 63(Rr-05), 1–30.PubMed Markowitz, L. E., Dunne, E. F., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J., & Unger, E. R. (2014). Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 63(Rr-05), 1–30.PubMed
Zurück zum Zitat Paavonen, J., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S. N., Apter, D., & Dubin, G. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. The Lancet, 374(9686), 301–314. https://doi.org/10.1016/s0140-6736(09)61248-4CrossRef Paavonen, J., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S. N., Apter, D., & Dubin, G. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. The Lancet, 374(9686), 301–314. https://​doi.​org/​10.​1016/​s0140-6736(09)61248-4CrossRef
Zurück zum Zitat Teitcher, J. E., Bockting, W. O., Bauermeister, J. A., Hoefer, C. J., Miner, M. H., & Klitzman, R. L. (2015). Detecting, preventing, and responding to “fraudsters” in Internet research: Ethics and tradeoffs. The Journal of Law, Medicine & Ethics, 43(1), 116–133.CrossRef Teitcher, J. E., Bockting, W. O., Bauermeister, J. A., Hoefer, C. J., Miner, M. H., & Klitzman, R. L. (2015). Detecting, preventing, and responding to “fraudsters” in Internet research: Ethics and tradeoffs. The Journal of Law, Medicine & Ethics, 43(1), 116–133.CrossRef
Zurück zum Zitat Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Group, T. D. F. S. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine, 367(5), 423–434. https://doi.org/10.1056/NEJMoa1110711CrossRef Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Group, T. D. F. S. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine, 367(5), 423–434. https://​doi.​org/​10.​1056/​NEJMoa1110711CrossRef
Zurück zum Zitat Zapata, J. P., Dang, M., Quinn, K. G., Horvath, K. J., Stephenson, R., Dickson-Gomez, J., & John, S. A. (2021). COVID-19-related disruptions to HIV testing and prevention among young sexual minority men 17–24 years old: A qualitative study using synchronous online focus groups, April-September 2020. Archives of Sexual Behavior, 51(1), 303–314. https://doi.org/10.1007/s10508-021-02166-7CrossRefPubMedPubMedCentral Zapata, J. P., Dang, M., Quinn, K. G., Horvath, K. J., Stephenson, R., Dickson-Gomez, J., & John, S. A. (2021). COVID-19-related disruptions to HIV testing and prevention among young sexual minority men 17–24 years old: A qualitative study using synchronous online focus groups, April-September 2020. Archives of Sexual Behavior, 51(1), 303–314. https://​doi.​org/​10.​1007/​s10508-021-02166-7CrossRefPubMedPubMedCentral
Metadaten
Titel
Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17–24 Years Old in the USA
verfasst von
Benedikt Pleuhs
Jennifer L. Walsh
Katherine G. Quinn
Andrew E. Petroll
Alan Nyitray
Steven A. John
Publikationsdatum
08.06.2022
Verlag
Springer US
Erschienen in
Sexuality Research and Social Policy / Ausgabe 4/2022
Print ISSN: 1868-9884
Elektronische ISSN: 1553-6610
DOI
https://doi.org/10.1007/s13178-022-00740-9

Weitere Artikel der Ausgabe 4/2022

Sexuality Research and Social Policy 4/2022 Zur Ausgabe